Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Antibody Disclosure Form This is a Word Form Template; please click on the GREY BOXES, fill in as appropriate. 1. Antibody Information (Completed by Investigator) Anti- (e.g Anti-CD61): Please delete as Monoclonal antibody / appropriate: Clone Name: Polyclonal antibody / Polyclonal Name: Isotype: For polyclonals: Amount available? (approx 5ml purified sera required for commercialisation) Raised in: Relevance (Application of antibody or relevance of target protein etc): Immunogen (please state it’s origin e.g. synthetic peptide sequence/location, recombinant protein, native protein from which species): Epitope (if known): Positive Control( (e.g. a tissue, cell type or cell line): Cross Reactivity: Applications tested(please delete as appropriate): ELISA ChIP Acetone Fixed RIA / / / / Other Applications (detail: Western Paraffin Embedded Frozen FITC ) / / / / / Neutralising Immunoprecipitation Immunofluorescence FACS / / / / Are there images available for any of the above (Images significantly increase commercial interest), please include in return message? Recommended Growth Conditions: Myeloma fusion partner used: Suggested dilutions in specified applications (If known): Published References (please include PubMedID): Registered office: Sardinia House, Sardinia Street, London WC2A 3NL. Registered in England number 1626049. VAT registration number GB788 138678. A wholly-owned subsidiary of Cancer Research UK, registered charity no. 1089464. Antibody Disclosure Form 2. Origin of Material (Completed by Investigator or CRT) Describe the origins / ownership of the immunogen used to general the antibody (the first line is an example) Immunogen/Antigen Origin Conditions of Transfer / Freedom of Use (Please include documentation) (e.g. Recombinant fragment of (e.g. Prof I Wood, (e.g. Academic MTA) human XYZ protein produced in E. [email protected]) coli (amino acids 123-153) ) 4. 3rd Party Institute Obligations (Funding Agency / Revenue Share / In-licensing). (Completed by Investigator or Newcastle Research & Enterprise Services or CRT) List ALL 3rd party institutes (host institutes / universities / charities / funding bodies) who have, or may claim to have co-ownership of the antibody, or who have contributed any funding, technology, material used to generate the antibody, describing their contribution and any proposed revenue share with the 3rd party institute or funding agency (the first line is an example line). 3rd Party institute Contribution Is Material (if Notes (host institute / corelevant) Covered owner IP) by TTA? e.g. MRC e.g. Primary Funder Not Applicable e.g. UCL e.g. recombinant e.g. No e.g. Revenue share and FTO will need to ABC protein via be assessed MTA 5. List ALL commercial technologies that have contributed to the generation of this antibody, or are included in the final product. (Completed by Investigator or CRT) Commercial 3rd Technology Notes Party e.g. Invitrogen e.g Green FP 6. Location of Reagent: (Completed by Investigator) Where is the hybridoma currently held (e.g. Investigator Lab)? Registered office: Sardinia House, Sardinia Street, London WC2A 3NL. Registered in England number 1626049. VAT registration number GB788 138678. A wholly-owned subsidiary of Cancer Research UK, registered charity no. 1089464.